Zacks Investment Research Downgrades Maximus (NYSE:MMS) to Sell

Zacks Investment Research lowered shares of Maximus (NYSE:MMS) from a hold rating to a sell rating in a research report report published on Tuesday, November 14th.

According to Zacks, “MAXIMUS, Inc. is an extremely dynamic and complex organization that offers government and industry a range of unique services, products, and solutions. The diverse services and products that MAXIMUS offers may be categorized into three groups: Government Program Management and Operations, Consulting, and Systems. Government Program Management and Operations focuses on having a measurable impact on the lives of the citizens we help government serve. The insights of MAXIMUS Consulting, and the technological innovations advanced through Systems, help government gain program efficiencies and pursue improvements that in turn benefit citizens. “

Other equities analysts have also issued reports about the stock. BidaskClub lowered shares of Maximus from a hold rating to a sell rating in a research report on Monday, July 24th. Maxim Group set a $66.00 price target on Maximus and gave the stock a hold rating in a research note on Thursday, August 3rd. Robert W. Baird reaffirmed a hold rating and set a $64.00 price target on shares of Maximus in a research note on Friday, September 1st. Finally, Canaccord Genuity cut their price target on Maximus from $62.00 to $61.00 and set a hold rating for the company in a research note on Friday, November 10th. Two investment analysts have rated the stock with a sell rating and six have issued a hold rating to the company’s stock. The company currently has an average rating of Hold and an average price target of $64.33.

Shares of Maximus (NYSE MMS) traded up $0.05 on Tuesday, hitting $69.18. 462,248 shares of the stock were exchanged, compared to its average volume of 295,866. Maximus has a twelve month low of $51.74 and a twelve month high of $69.20. The stock has a market capitalization of $4,506.18, a price-to-earnings ratio of 22.24, a PEG ratio of 2.60 and a beta of 1.35.

The company also recently announced a quarterly dividend, which was paid on Thursday, November 30th. Stockholders of record on Wednesday, November 15th were issued a dividend of $0.045 per share. This represents a $0.18 dividend on an annualized basis and a dividend yield of 0.26%. The ex-dividend date was Tuesday, November 14th. Maximus’s payout ratio is currently 5.66%.

In other Maximus news, President Bruce Caswell sold 8,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $60.23, for a total value of $481,840.00. Following the completion of the transaction, the president now owns 35,904 shares in the company, valued at approximately $2,162,497.92. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Russell A. Beliveau sold 1,500 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $64.30, for a total value of $96,450.00. Following the completion of the transaction, the director now directly owns 40,329 shares in the company, valued at $2,593,154.70. The disclosure for this sale can be found here. Insiders have sold a total of 91,717 shares of company stock valued at $5,903,675 in the last quarter. Company insiders own 3.10% of the company’s stock.

Hedge funds have recently bought and sold shares of the stock. Acrospire Investment Management LLC grew its stake in Maximus by 17.6% during the 2nd quarter. Acrospire Investment Management LLC now owns 2,000 shares of the health services provider’s stock worth $125,000 after buying an additional 300 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Maximus by 10.2% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,367 shares of the health services provider’s stock worth $148,000 after purchasing an additional 220 shares in the last quarter. First Bank & Trust grew its stake in shares of Maximus by 4.2% in the second quarter. First Bank & Trust now owns 2,507 shares of the health services provider’s stock worth $157,000 after purchasing an additional 101 shares in the last quarter. Intl Fcstone Inc. bought a new position in Maximus during the second quarter valued at about $201,000. Finally, GW Henssler & Associates Ltd. bought a new position in Maximus during the second quarter valued at about $205,000. 95.22% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This report was first posted by BBNS and is owned by of BBNS. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://baseballnewssource.com/markets/maximus-inc-mms-lowered-to-sell-at-zacks-investment-research/1782898.html.

Maximus Company Profile

MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.

Get a free copy of the Zacks research report on Maximus (MMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Maximus (NYSE:MMS)

Receive News & Ratings for Maximus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees


Leave a Reply

 
© 2006-2017 BBNS.